Clinicians managing cancer patients can have confidence in the equivalence of biosimilar products to the original reference molecule when it comes to efficacy, safety and when switching between products, a new Australian consensus statement advises. With the emergence of biosimilar brands for biologic agents used in haematological cancer such as rituximab, clinicians and patients need ...
Cancer clinicians reassured on biosimilar equivalence and switching
By Michael Woodhead
16 Apr 2020